Want to see GRCE full AI Analyst Report?
GRCE Stock Chart & Stats
$2.33
-$0.02(-0.85%)
At close: 4:00 PM EDT
$2.33
-$0.02(-0.85%)
Day’s Range― - ―
52-Week Range$1.79 - $5.18
Previous CloseN/A
Volume127.09K
Average Volume (3M)58.56K
Market Cap
$45.44M
Enterprise Value$25.45
Total Cash (Recent Filing)$13.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Nov 16, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding21,035,930
10 Day Avg. Volume55,886
30 Day Avg. Volume58,559
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.20
Price to Sales (P/S)0.00
P/FCF Ratio-8.62
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetMinimal debt and a conservatively financed balance sheet reduce refinancing risk and give management flexibility to fund R&D, manufacturing tech transfers, and regulatory activities. This structural low-leverage profile supports multi-quarter execution even amid recurring losses.
Improving Cash Burn TrendMaterial improvement in operating cash outflow signals better cost control and operational discipline. A sustained reduction in burn rate increases the durability of existing cash runway, reducing near-term financing frequency and giving more time to complete regulatory and manufacturing milestones.
Positive Phase 3 And Manufacturing MitigationA successful Phase 3 with no clinical deficiencies in the CRL, combined with orphan status and a dual-source manufacturing plan, strengthens the program's regulatory and commercial prospects. Multi-source manufacturing reduces single-vendor risk and supports a viable regulatory resubmission pathway.
Bears Say
No Commercial RevenueZero reported revenue leaves the company dependent entirely on successful NDA resubmission and future commercialization. This eliminates operating margin visibility, prevents internal funding of development, and makes long-term viability contingent on achieving and monetizing regulatory approval.
Reliance On External FinancingA material equity raise to extend runway illustrates dependency on capital markets to fund operations and regulatory work. Continued negative free cash flow means recurring financing risk and potential dilution until commercialization or positive cash generation is achieved.
Manufacturing & CMC Execution RiskFDA concerns about a contract manufacturer's cGMP compliance and the need for either remediation or a full tech transfer create a structural execution risk. The requirement for stability data and potential reinspection can meaningfully delay approval and revenue realization.
Grace Therapeutics News
GRCE FAQ
What was Grace Therapeutics’s price range in the past 12 months?
Grace Therapeutics lowest stock price was $1.79 and its highest was $5.18 in the past 12 months.
What is Grace Therapeutics’s market cap?
Grace Therapeutics’s market cap is $45.44M.
When is Grace Therapeutics’s upcoming earnings report date?
Grace Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 90 days.
How were Grace Therapeutics’s earnings last quarter?
Grace Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.91 earnings per share for the quarter, missing the consensus estimate of -$0.129 by -$0.781.
Is Grace Therapeutics overvalued?
According to Wall Street analysts Grace Therapeutics’s price is currently Overvalued.
Does Grace Therapeutics pay dividends?
Grace Therapeutics does not currently pay dividends.
What is Grace Therapeutics’s EPS estimate?
Grace Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Grace Therapeutics have?
Grace Therapeutics has 21,035,930 shares outstanding.
What happened to Grace Therapeutics’s price movement after its last earnings report?
Grace Therapeutics reported an EPS of -$0.91 in its last earnings report, missing expectations of -$0.129. Following the earnings report the stock price went down -1.429%.
Which hedge fund is a major shareholder of Grace Therapeutics?
Currently, no hedge funds are holding shares in GRCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grace Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.1%
Last 30 Days ▼ 8.3%
Last 30 Days ▼ 8.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.48%
Trailing 12-Months
Company Description
Grace Therapeutics
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
GRCE Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
6.24%
Insiders
1.94% Mutual Funds
7.30% Other Institutional Investors
82.46% Public Companies and
Individual Investors